Literature DB >> 22367926

Meta-analysis of self-reported substance use compared with laboratory substance assay in general adult mental health settings.

Matthew M Large1, Glen Smith, Grant Sara, Michael B Paton, Karina Karolina Kedzior, Olav B Nielssen.   

Abstract

An accurate assessment of substance use is necessary to make a correct psychiatric diagnosis and to provide appropriate treatment. This study uses meta-analysis to establish the strength of the association between self-reported substance use and the results of laboratory substance assay including the testing for specific substances and screening for any substance use in psychiatric hospitals and in community mental health settings. A systematic search for published studies was supplemented by additional data required for meta-analysis provided by several researchers in this field. Using random-effects meta-analysis, we calculated the pooled estimate of the odds ratio of a positive substance assay in patients reporting use or non-use of substances and estimated the sensitivity, specificity, positive predictive value and negative predictive value. Twenty-six studies met the inclusion criteria. Very strong associations were found between self-reported use and positive tests for cannabis [N = 11 studies, odds ratio (OR) = 22.3; 95% confidence interval (CI) = 10.1-49.1], amphetamines (N = 8, OR = 26.6; 95% CI = 7.9-88.9), cocaine (N = 8, OR = 39.7; 95% CI = 16.2-97.2) and opiates (N = 7, OR = 83.5; 95% CI = 26.7-260.7). Strong associations were found between self-reported use of any substance and positive substance screening (N = 15, OR = 7.2, 95% CI = 3.6-14.1) and tests for alcohol use (N = 5, OR = 8.5; 95% CI = 2.5-28.4). Screening for any substance use had a sensitivity of 61% and a specificity of 66%. Testing for individual substances was specific but lacked sensitivity. Screening has the potential to detect clinically relevant substances that would not be reported by the patient, whereas testing for a specific substance has little advantage over self-report. The sensitivity of the substance assay might be improved by obtaining a sample at the earliest opportunity. Consideration should be given to the increased use of substance screening in general adult mental health settings because it could improve the accuracy of psychiatric diagnosis and increase the likelihood of patients receiving treatment for substance use disorders.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22367926      PMCID: PMC6878377          DOI: 10.1002/mpr.1350

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  49 in total

1.  Utility of routine drug screening in a psychiatric emergency setting.

Authors:  M J Schiller; M Shumway; S L Batki
Journal:  Psychiatr Serv       Date:  2000-04       Impact factor: 3.084

2.  Use of potentially abusive psychotropic substances in psychiatric inpatients.

Authors:  J Modestin; C Nussbaumer; K Angst; P Scheidegger; D Hell
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

3.  Simultaneous screening and quantification of 29 drugs of abuse in oral fluid by solid-phase extraction and ultraperformance LC-MS/MS.

Authors:  Nora Badawi; Kirsten Wiese Simonsen; Anni Steentoft; Inger Marie Bernhoft; Kristian Linnet
Journal:  Clin Chem       Date:  2009-10-01       Impact factor: 8.327

4.  Amphetamine psychosis. II. Theoretical implications.

Authors:  E H Ellinwood
Journal:  Int J Neuropsychiatry       Date:  1968-02

5.  Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.

Authors:  S Andréasson; P Allebeck; A Engström; U Rydberg
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

6.  Utility of Hair, Urine, and Self-Report to Monitor Drug Use in Research Studies including People with Schizophrenia.

Authors:  Nancy H Covell; Susan M Essock
Journal:  J Dual Diagn       Date:  2008-10-01

7.  Hair analysis for cannabinoids and amphetamines in a psychosis incidence study.

Authors:  Jean-Paul Selten; Ingrid J Bosman; Douwe de Boer; Natalie D Veen; Yolanda van der Graaf; Robert A A Maes; René S Kahn
Journal:  Eur Neuropsychopharmacol       Date:  2002-02       Impact factor: 4.600

8.  Detection of illicit substance use among persons with schizophrenia by radioimmunoassay of hair.

Authors:  Marvin S Swartz; Jeffrey W Swanson; Michael J Hannon
Journal:  Psychiatr Serv       Date:  2003-06       Impact factor: 3.084

9.  Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

Authors:  Diana O Perkins; Hongbin Gu; Peter J Weiden; Joseph P McEvoy; Robert M Hamer; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2008-01       Impact factor: 4.384

10.  Substance abuse in hospitalized psychiatric patients.

Authors:  Gregory Katz; Rimona Durst; Emi Shufman; Rachel Bar-Hamburger; Leon Grunhaus
Journal:  Isr Med Assoc J       Date:  2008-10       Impact factor: 0.892

View more
  9 in total

1.  Developing an Integrated Violence Prevention for Men and Women in Treatment for Substance Use Disorders.

Authors:  Stephen T Chermack; Erin E Bonar; Mark A Ilgen; Maureen A Walton; Rebecca M Cunningham; Brenda M Booth; Frederic C Blow
Journal:  J Interpers Violence       Date:  2016-07-11

2.  Carvedilol Among Patients With Heart Failure With a Cocaine-Use Disorder.

Authors:  Dahlia Banerji; Raza M Alvi; Maryam Afshar; Noor Tariq; Adam Rokicki; Connor P Mulligan; Lili Zhang; Malek O Hassan; Magid Awadalla; John D Groarke; Tomas G Neilan
Journal:  JACC Heart Fail       Date:  2019-09       Impact factor: 12.035

3.  Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis".

Authors:  Eric R Braverman; Catherine A Dennen; Mark S Gold; Abdalla Bowirrat; Ashim Gupta; David Baron; A Kenison Roy; David E Smith; Jean Lud Cadet; Kenneth Blum
Journal:  Int J Environ Res Public Health       Date:  2022-04-30       Impact factor: 4.614

4.  Distal and proximal factors associated with aggression towards partners and non-partners among patients in substance abuse treatment.

Authors:  Quyen M Epstein-Ngo; Maureen A Walton; Michelle Sanborn; Shane Kraus; Fred Blow; Rebecca Cunningham; Stephen T Chermack
Journal:  J Subst Abuse Treat       Date:  2014-06-10

5.  Concordance between self-reported substance use and toxicology among HIV-infected and uninfected at risk youth.

Authors:  Sharon L Nichols; Amanda Lowe; Xinrui Zhang; Patricia A Garvie; Sarah Thornton; Bruce A Goldberger; Wei Hou; Maureen M Goodenow; John W Sleasman
Journal:  Drug Alcohol Depend       Date:  2013-11-19       Impact factor: 4.492

6.  Practice effects on the modified concept shifting task (mCST): a convenient assessment for treatment effects on prefrontal cognitive function.

Authors:  Karina K Kedzior; Stuti Kochhar; Hannah S Eich; Vikram Rajput; Mathew T Martin-Iverson
Journal:  BMC Neurosci       Date:  2011-10-11       Impact factor: 3.288

7.  A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies.

Authors:  Karina Karolina Kedzior; Lisa Tabata Laeber
Journal:  BMC Psychiatry       Date:  2014-05-10       Impact factor: 3.630

8.  The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.

Authors:  Diego Quattrone; Ulrich Reininghaus; Alex L Richards; Giada Tripoli; Laura Ferraro; Andrea Quattrone; Paolo Marino; Victoria Rodriguez; Edoardo Spinazzola; Charlotte Gayer-Anderson; Hannah E Jongsma; Peter B Jones; Caterina La Cascia; Daniele La Barbera; Ilaria Tarricone; Elena Bonora; Sarah Tosato; Antonio Lasalvia; Andrei Szöke; Celso Arango; Miquel Bernardo; Julio Bobes; Cristina Marta Del Ben; Paulo Rossi Menezes; Pierre-Michel Llorca; Jose Luis Santos; Julio Sanjuán; Manuel Arrojo; Andrea Tortelli; Eva Velthorst; Steven Berendsen; Lieuwe de Haan; Bart P F Rutten; Michael T Lynskey; Tom P Freeman; James B Kirkbride; Pak C Sham; Michael C O'Donovan; Alastair G Cardno; Evangelos Vassos; Jim van Os; Craig Morgan; Robin M Murray; Cathryn M Lewis; Marta Di Forti
Journal:  Transl Psychiatry       Date:  2021-08-10       Impact factor: 6.222

9.  Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.

Authors:  Diego Quattrone; Laura Ferraro; Giada Tripoli; Caterina La Cascia; Harriet Quigley; Andrea Quattrone; Hannah E Jongsma; Simona Del Peschio; Giusy Gatto; Charlotte Gayer-Anderson; Peter B Jones; James B Kirkbride; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Sarah Tosato; Antonio Lasalvia; Andrei Szöke; Celso Arango; Miquel Bernardo; Julio Bobes; Cristina Marta Del Ben; Paulo Rossi Menezes; Pierre-Michel Llorca; Jose Luis Santos; Julio Sanjuán; Andrea Tortelli; Eva Velthorst; Lieuwe de Haan; Bart P F Rutten; Michael T Lynskey; Tom P Freeman; Pak C Sham; Alastair G Cardno; Evangelos Vassos; Jim van Os; Craig Morgan; Ulrich Reininghaus; Cathryn M Lewis; Robin M Murray; Marta Di Forti
Journal:  Psychol Med       Date:  2020-03-18       Impact factor: 7.723

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.